Effects of preshipping vs arrival medication with tilmicosin phosphate andfeeding chlortetracycline on health and performance of newly received beefcattle
Gc. Duff et al., Effects of preshipping vs arrival medication with tilmicosin phosphate andfeeding chlortetracycline on health and performance of newly received beefcattle, J ANIM SCI, 78(2), 2000, pp. 267-274
Our objective was to determine the effects of preshipping (PRE) vs arrival
(ARR) medication with tilmicosin phosphate (MIC; Exp. 1 and 2) and feeding
chlortetracycline (CTC; 22 mg/kg of BW from d 5 to 9; Exp. 2) on health and
performance of beef calves received in the feedlot. Ninety-six steers (Exp
. 1; pay weight 236 kg) and 240 (Exp. 2; average pay weight 188 kg) steer a
nd bull calves were used. For Exp. 1, treatments included no MIC (CON), PRE
, and ARR. For Exp. 2, treatments were arranged in a 3 x 2 factorial. Treat
ments included CON, PRE, and ARR, either with CTC or without CTC. For Exp.
2, serum concentrations of immunoglobulin (Ig)G and alpha-1-acid glycoprote
in (AGP) were determined on samples collected on d 0, 5, 10, and 28 and d 0
, 5, and 10, respectively. No MIC x CTC interactions were observed. No diff
erences were noted among MIC or CTC treatments in any of the experiments fo
r ADG, daily DMI, or gain:feed ratio for the overall receiving periods. For
Exp. 1, percentage of steers treated for bovine respiratory disease (BRD)
was decreased (P <.05) for MIG-treated animals vs CON (71.9, 45.2, and 46.9
for CON, PRE, and ARR, respectively), and the week that calves were treate
d for BRD differed (P <.10) among treatments. For Exp. 2, the number of cal
ves treated for BRD was decreased (P <.01) for MIC-treated steers vs CON an
d decreased (P <.05) for ARR vs PRE (40.0, 18.7, and 7.5% for CON, PRE, and
ARR, respectively). Averaged across days, serum IgG was decreased (P <.05)
for MIG-treated steers vs CON, with no differences noted among treatments
for AGP. Results suggest that preshipping medication programs are no more e
ffective than arrival medication programs using tilmicosin phosphate.